SG11201906671SA - Compositions and methods for inhibiting reticulon 4 - Google Patents
Compositions and methods for inhibiting reticulon 4Info
- Publication number
- SG11201906671SA SG11201906671SA SG11201906671SA SG11201906671SA SG11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA SG 11201906671S A SG11201906671S A SG 11201906671SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- co7c
- compositions
- methods
- oakland
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762454681P | 2017-02-03 | 2017-02-03 | |
US201762471865P | 2017-03-15 | 2017-03-15 | |
PCT/US2018/016650 WO2018144870A1 (fr) | 2017-02-03 | 2018-02-02 | Compositions et méthodes permettant d'inhiber l'inhibiteur reticulon 4 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906671SA true SG11201906671SA (en) | 2019-08-27 |
Family
ID=63040209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906671SA SG11201906671SA (en) | 2017-02-03 | 2018-02-02 | Compositions and methods for inhibiting reticulon 4 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200062696A1 (fr) |
EP (1) | EP3576728A4 (fr) |
JP (1) | JP2020506935A (fr) |
KR (1) | KR20190126074A (fr) |
CN (1) | CN110461322A (fr) |
AU (1) | AU2018215447A1 (fr) |
BR (1) | BR112019016132A2 (fr) |
CA (1) | CA3051587A1 (fr) |
MX (1) | MX2019009200A (fr) |
SG (1) | SG11201906671SA (fr) |
WO (1) | WO2018144870A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112930337A (zh) * | 2018-08-24 | 2021-06-08 | 赛尼欧普罗有限责任公司 | 抗增殖活性的苯氧基(杂)芳基醚 |
CN115103670A (zh) * | 2019-12-24 | 2022-09-23 | 达纳-法伯癌症研究所股份有限公司 | 转录增强相关结构域(tead)转录因子抑制剂及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL102790A (en) * | 1991-09-17 | 1996-01-31 | Roussel Uclaf | History of 3-cycloalkyl-prop-2-anamide |
US5922775A (en) * | 1997-10-23 | 1999-07-13 | Octamer, Inc. | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
US7928127B2 (en) * | 2005-05-19 | 2011-04-19 | Notre Dame University | Inhibitors of matrix metallaproteinases |
US8828390B2 (en) * | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
WO2012164103A2 (fr) * | 2011-06-03 | 2012-12-06 | Universität Zürich | Bloqueurs de la voix nogo-a s1pr pour le traitement de maladies caractérisées par une lésion neuronale et un défaut de réparation ultérieure |
TWI507191B (zh) * | 2011-08-03 | 2015-11-11 | 國立陽明大學 | 含src同源區2蛋白酪胺酸磷酸酶-1增效劑及其治療方法 |
CN104203242B (zh) * | 2012-04-04 | 2017-03-15 | 杭州德润玉成生物科技有限公司 | 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂 |
EP3033625B1 (fr) * | 2013-08-13 | 2020-01-22 | The Scripps Research Institute | Découverte de ligand réactif à la cystéine dans des protéomes |
CA2940272C (fr) * | 2014-02-28 | 2022-03-29 | Tohoku University | Derive d'amide |
EP3131875A4 (fr) * | 2014-04-16 | 2018-04-04 | Nanyang Technological University | Allénamide formant poignée orthogonale pour une modification sélective de la cystéine dans des peptides et des protéines |
AU2016209046A1 (en) * | 2015-01-23 | 2017-07-20 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
WO2017070611A1 (fr) * | 2015-10-22 | 2017-04-27 | The Scripps Research Institute | Sondes réactives à la cystéine et utilisations associées |
-
2018
- 2018-02-02 JP JP2019542113A patent/JP2020506935A/ja active Pending
- 2018-02-02 CN CN201880020332.2A patent/CN110461322A/zh active Pending
- 2018-02-02 CA CA3051587A patent/CA3051587A1/fr not_active Abandoned
- 2018-02-02 WO PCT/US2018/016650 patent/WO2018144870A1/fr unknown
- 2018-02-02 KR KR1020197025643A patent/KR20190126074A/ko unknown
- 2018-02-02 SG SG11201906671SA patent/SG11201906671SA/en unknown
- 2018-02-02 EP EP18747169.3A patent/EP3576728A4/fr not_active Withdrawn
- 2018-02-02 AU AU2018215447A patent/AU2018215447A1/en not_active Abandoned
- 2018-02-02 BR BR112019016132A patent/BR112019016132A2/pt not_active Application Discontinuation
- 2018-02-02 US US16/482,947 patent/US20200062696A1/en not_active Abandoned
- 2018-02-02 MX MX2019009200A patent/MX2019009200A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3576728A4 (fr) | 2020-08-12 |
CN110461322A (zh) | 2019-11-15 |
WO2018144870A1 (fr) | 2018-08-09 |
BR112019016132A2 (pt) | 2020-04-07 |
JP2020506935A (ja) | 2020-03-05 |
EP3576728A1 (fr) | 2019-12-11 |
CA3051587A1 (fr) | 2018-08-09 |
MX2019009200A (es) | 2019-10-21 |
AU2018215447A1 (en) | 2019-08-08 |
KR20190126074A (ko) | 2019-11-08 |
US20200062696A1 (en) | 2020-02-27 |
WO2018144870A8 (fr) | 2019-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201906395PA (en) | Blockchain based data processing method and device | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201900596XA (en) | Cannabis composition | |
SG11201900501RA (en) | Cannabis composition | |
SG11201804041QA (en) | High conductivity graphane-metal composite and methods of manufacture | |
SG11201902857SA (en) | Activatable anti-ctla-4 antibodies and uses thereof | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11202000131VA (en) | Substituted aluminum nitride for improved acoustic wave filters | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201807770RA (en) | Sequence arrangements and sequences for neoepitope presentation | |
SG11201805164WA (en) | Programmable universal quantum annealing with co-planar waveguide flux qubits | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
SG11201809395XA (en) | Executable logic for processing keyed data in networks | |
SG11201900665VA (en) | Cannabis composition | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof |